|
WO2021050648A1
|
|
Methods of treating cancer
|
|
WO2020176497A1
|
|
High-affinity anti-mertk antibodies and uses thereof
|
|
WO2019104062A1
|
|
Polymorphs and uses thereof
|
|
WO2018222975A1
|
|
Methods for the treatment of cancer
|
|
US2018251422A1
|
|
Formulations with improved stability
|
|
WO2018160178A1
|
|
Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
|
|
US2017056352A1
|
|
PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
|
|
WO2016176636A1
|
|
Inhibitors of creatine transport and uses thereof
|
|
US2019125745A1
|
|
Treatment and diagnosis of cancer
|
|
WO2015168465A1
|
|
Inhibitors of creatine transport and uses thereof
|
|
AU2015204572A1
|
|
LXR agonists and uses thereof
|
